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INTRODUCTION
Gonadotropin-releasing hormone (GnRH) antagonists
have been widely used for the prevention of premature luteiniz-
ing hormone (LH) surges during controlled ovarian hyper-
stimulation (COH) for in vitro fertilization and embryo trans-
fer (IVF-ET) since the late 1990’s (1). Applying the GnRH
antagonists for COH in assisted reproductive technology
(ART) leads to a dramatic reduction in the duration of GnRH
analogue treatment or the amount of gonadotropins needed
for stimulation, decreases the risk of developing severe ovar-
ian hyperstimulation syndrome (OHSS), and avoids estro-
gen deprivation symptoms such as hot flushes and sleep dis-
turbance (2). 
However, the first meta-analysis including the five com-
parative studies compared with long agonist protocols iden-
tified 5% less clinical pregnancies in the antagonist groups
(3). Thereafter, the role of LH in follicular development
becomes again a matter of debate, because GnRH antago-
nists can completely deprive serum LH at a critical stage of
follicular development. In view of the decreased probability
of pregnancy associated with low LH levels, it has been demon-
strated that there is a dose-related decline in the implanta-
tion rates when high doses of ganirelix were used (4). Simi-
lar effects were observed when human menopausal gonado-
tropin (hMG) leads to a significantly higher clinical preg-
nancy rate than recombinant follicle stimulating hormone
(rFSH) alone in IVF cycles of patients with normogonadotrop-
ic GnRH agonist down regulation (5). Moreover, in many
studies, GnRH antagonist protocols have been associated
with significantly lower serum estradiol levels on the day of
hCG administration and a significantly lower number of
retrieved oocytes than GnRH agonist protocols (6, 7). 
The subsequent meta-analyses have been reported but the
results are quite conflicting (8, 9). Such conflicting results
might be the consequence of variable regimens of GnRH
antagonist utilized (10) or different starting doses of FSH
(6). The confusing data from several comparative studies
made the GnRH antagonist to be a second choice for many
clinicians. Almost all of the studies identified that GnRH
antagonists were often used in cycles with an unfavorable
previous prognosis, old age and higher number of previous-
ly failed cycles (11). Until now, it is still controversial that
GnRH antagonists have adverse effect on clinical pregnancy
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Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering
Day: An Alternative Method for Flexible Multiple-Dose Protocol
This study was performed to analyze retrospectively outcomes of stimulated in
vitro fertilization (IVF) cycles where the gonadotropin-releasing hormone (GnRH)
antagonist was omitted on ovulation triggering day. A total of 92 consecutive IVF
cycles were included in 65 women who are undergoing ovarian stimulation with
recombinant FSH. A GnRH antagonist, cetrorelix 0.25 mg/day, was started when lead-
ing follicle reached 14 mm in diameter until the day of hCG administration (Group
A, 66 cycles) or until the day before hCG administration (Group B, 26 cycles). The
duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels
on hCG administration day, and the number of oocytes retrieved were not signifi-
cantly different between the two groups. The total dose of GnRH antagonist was
significantly lower in Group B compared to Group A (2.7± ±0.8 vs. 3.2± ±0.9 ampou-
les). There was no premature luteinization in the subjects. The proportion of mature
oocytes (71.4% vs. 61.7%) and fertilization rate of mature (86.3± ±19.7% vs. 71.8± ±
31.7%) was significantly higher in Group B. There were no significant differences
in embryo quality and clinical pregnancy rates. Our results suggest that cessation
of the GnRH antagonist on the day of hCG administration during a flexible multiple-
dose protocol could reduce the total dose of GnRH antagonist without compromis-
ing IVF results. 
Key Words : GnRH Antagonist; hCG Administration; Oocyte Maturation; Fertilization; Ovulation Induction;
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rates, thus optimal regimens of GnRH antagonist have not
been established.
On the basis of the negative impact of GnRH antagonist
on COH outcome, many attempts to modify GnRH antag-
onist protocols have been made to improve the COH out-
comes. These include pretreatment with 17β -estradiol, inter-
cycle administration of a GnRH antagonist, pretreatment
with oral contraceptives (12), modifications of initiation
timing (13), and administration of GnRH antagonist before
ovarian stimulation in an attempt to lengthen the follicular
phase in the poor responder (14). However, there is still no
consensus on the optimal GnRH antagonist protocol. Thus,
additional efforts are needed to identify the optimal stimu-
lation protocols to achieve better follicular and embryonic
development and to improve the pregnancy rates in COH
using GnRH antagonist.
Inhibitory action of GnRH antagonists can be reversed
immediately when GnRH antagonist discontinued. Due to
the nature of its competitive blockade of GnRH action at
the receptor level, the degree of gonadal suppression can be
controlled by the dose of the GnRH antagonist. Pulsatile
release of LH by the pituitary was significantly suppressed
by the GnRH antagonist for 456 min (7.6 hr), followed by
a period of secretory pulses with decreased amplitude and
pulse mass (15). Therefore, discontinuing the administra-
tion of a GnRH antagonist on hCG day would efficiently
prevent premature LH surge. Moreover, given the assump-
tion of a potential disadvantage of GnRH antagonist with
current protocols on the pregnancy rate, we hypothesized
that a shorter duration of GnRH antagonist administration
might improve IVF outcome. Therefore, we investigated
the outcomes of cycle in which GnRH antagonist was admin-
istrated till the day before hCG administration in flexible
multiple-dose protocols. This is the first study to demon-
strate that GnRH antagonist can be safely omitted on the
triggering day.
MATERIALS AND METHODS
Patients
Ninety-two eligible IVF cycles in 65 women who under-
went COH with recombinant FSH and GnRH antagonist
flexible multiple-dose protocols between July 2004 and
December 2006 were included in this retrospective study.
The following selection criteria were adopted: 1) the women
of 40 yr old or less, 2) both ovaries present with no morpho-
logical abnormalities, 3) normal ovulatory women with
cycle lengths between 25 and 35 days, 4) a basal serum FSH
(day 3) level of <15 mIU/mL, 5) no history of a poor ovari-
an response, 6) body mass index (BMI) ranged between 18
and 27 kg/m2, and 7) no evidence of endocrine abnormali-
ties, such as, hyperprolactinemia, thyroid dysfunction, or
polycystic ovary syndrome, as defined by the Rotterdam
criteria (22). Patients with hydrosalpinx, severe endometrio-
sis (stage III-IV), and frozen-thawing cycles were excluded
from the study. All patients had a normal uterine cavity doc-
umented either by hysterosalpingography or hysteroscopy
performed within one year before entering into the study.
The Patients were divided into two groups according to
the administration of the GnRH antagonist on hCG day:
the GnRH antagonist was administered daily until the day
of hCG administration (Group A, 66 cycles) or the day before
hCG administration (Group B, 26 cycles). This study was
approved by the Institutional Review Board of Seoul Nation-
al University Bundang Hospital.
Controlled ovarian hyperstimulation protocols
Recombinant FSH (Gonal-F; Serono, Geneva, Switzerland)
was started on the second or third day of the menstrual cycle
without previous oral contraceptive pretreatment. The GnRH
antagonist, cetrorelix acetate (Cetrotide; Serono, Geneva,
Switzerland) 0.25 mg was added daily, starting when the
leading follicle reached 14 mm in diameter. When the lead-
ing follicle reached a mean diameter of 18 mm or two follicles
or more reached a diameter of 17 mm, 10,000 IU of urinary
hCG (Pregnyl; Organon, Oss, Netherlands) IM or 250 μ g
of recombinant hCG (Ovidrel; Serono, Geneva, Switzerland)
SQ was injected. In Group A, the GnRH antagonist con-
tinued to be used until the day of hCG administration. In
Group B, the GnRH antagonist was not administrated on
the hCG day (Fig. 1). After the hCG injection, oocyte retrieval
was performed 35 to 36 hr later. 
Fig. 1. Schematic diagram of controlled ovarian hyperstimulation
protocol. On the menstrual cycle day 3, recombinant FSH was
started at adjusted dose individually. Once the largest follicle
reached 14 mm in diameter, 0.25 mg of GnRH antagonist was
started. 10,000 IU of urinary hCG (u-hCG) or 250 μ g of recombi-
nant hCG (r-hCG) was administrated when leading follicle reached
18 mm in diameter. GnRH antagonist was administered daily
until the day of hCG administration (Group A) or the day before
hCG administration (Group B). 
Group A
Group B
Recombinant FSH
Ovum pick-up
u-hCG 10,000 IU
/ r-hCG 250 μ g
Follicle size
≥14 mm
Follicle size
≥18 mm
MCD#3
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At the time of oocyte retrieval, the maturity of the oocytes
was assessed. They were classified as mature (MII), interme-
diate, immature oocytes (including germinal vesicle) accord-
ing to the cumulus/corona morphology, cytoplasmic clarity,
zona thickness, and the extent of the perivitelline space. 
Fertilization and embryo transfer
After oocyte maturation was achieved, the oocytes were
inseminated with fresh pretreated sperm. If there was a failed
fertilization in previous IVF cycles or the cause of infertility
was due to a male factor, intracytoplasmic sperm injection
(ICSI) was performed. Fertilization was assessed 16 to 18 hr
after insemination or injection, where the presence of two
pronuclei was recorded as a normal fertilization. Up to four
embryos were transferred 2 or 3 days after the oocyte retrieval. 
Embryonic development was assessed morphologically
based on four grading system according to the regularity of
blastomeres, the percentage of anucleate fragments, and the
dysmorphic characteristic of the embryos: 1) grade I: 0% anu-
cleate fragments, regularity of blastomeres and no apparent
morphologic abnormalities, 2) grade II: <20% anucleate
fragments, regularity of blastomeres and no apparent mor-
phologic abnormalities, 3) grade III: 20-50% anucleate frag-
ments, irregularity of blastomeres and no apparent morpho-
logic abnormalities, 4) grade IV: >50% anucleate fragmen-
tation, irregularity of blastomeres and apparent morpholog-
ic abnormalities. Cumulative embryo score (CES) was calcu-
lated as the number of blastomeres multiplied by the mor-
phologic score of embryo (I=4, II=3, III=2, IV=1). The scores
were summed to obtain the CES of all embryos transferred
per patient. The mean CES was calculated as dividing CES
by number of embryos and used as an indicator of embryo
quality.
Pregnancy was initially assessed using serum β -hCG at
14 days after oocyte retrieval. Progesterone in oil (Progest;
Samil, Seoul, Korea) 50 mg/day IM was started from the day
of oocyte retrieval until pregnancy testing, and continued
until 8 weeks if pregnant. Clinical pregnancy was defined
by the presence of an intrauterine gestational sac with visi-
ble fetal heartbeats 3 to 4 weeks after embryo transfer.
Hormonal measurements
In the morning of triggering day, the patients’ sera were
obtained and serum levels of LH, progesterone and estradiol
(E2) were determined. Serum levels of LH were measured by
immunoradiometric assay (IRMA) using a commercial kit
(Biosource, Nivelles, Belgium). The detection limit, intra-
and inter-assay coefficients of variation (CVs) were 0.2 mIU/
mL, 3.2% and 6.7%, respectively. Radioimmunoassay (RIA)
was used to measure estradiol and progesterone concentra-
tions using commercial kits (Biosourc). The detection lim-
its and the intra- and interassay CVs were 10 pg/mL, 4.9%,
and 5.2% for E2, and 0.02 ng/mL, 3.3%, and 7.1% for pro-
gesterone, respectively. 
A premature LH rise was defined as LH ≥10 mIU/mL
and a premature progesterone rise as progesterone ≥1.0 ng/
mL. The combination of the above-mentioned conditions
(LH ≥10 mIU/mL and progesterone ≥1.0 ng/mL) was
indicated as premature luteinization, as previously described
(16). 
Statistical analysis
The data were analyzed using the Student’s t-test for con-
tinuous variables, and the chi-square or Fisher’s exact tests for
categorical variables. The statistical software package SPSS,
version 12.0 (SPSS Inc., Chicago, IL, U.S.A.), was used for
statistical analysis, and a p<0.05 was considered to be statis-
tically significant.
RESULTS
The patient characteristics are described in Table 1. There
were no statistically significant differences in age, body mass
index, duration of infertility, basal serum FSH levels, and
distribution of the causes of infertility between the two groups.
There was no case with premature ovulation in this study
subjects. The duration of COH, total doses of gonadotropins
used, serum E2 levels on hCG day, and number of retrieved
oocytes were not significantly different between the two
groups (Table 2). As expected, total doses of GnRH antago-
nist used were significantly lower in Group B compared to
Group A. 
Although the number of mature follicles (defined as mean
diameter ≥15 mm) on hCG day and the retrieved oocytes
were not significantly different between the two groups, the
ratio of mature per total retrieved oocytes was higher in Group
B. The fertilization rate of the mature and total oocytes was
significantly higher in Group B. The number of embryos
transferred and embryo quality did not differ between the
Values are mean±SD.
ICSI, intracytoplasmic sperm injection; NS, not significant.
Group A 
(n=66)
Group B
(n=26)
p
value
Women’s age (yr) 34.7±4.8 32.9±5.5 NS
Body mass index (kg/m
2) 21.4±1.8 20.8±2.2 NS
Duration of infertility (yr) 4.0±2.8 3.1±1.8 NS
Basal serum FSH (mIU/mL) 6.9±5.6 7.1±3.2 NS
Cause of infertility (%) NS
Tubal factor 47.0  50.0 
Male factor 28.8  26.9 
Unexplained 24.2 23.1 
Cases of underwent ICSI (%) 60.6 51.7 NS
Table 1. Clinical characteristics of study subjectsCessation of GnRH Antagonist on hCG Day 265
two groups.
The mean endometrial thicknesses (9.8±2.3 mm vs. 10.5
±3.4 mm) and rates of a trilaminar endometrial pattern on
hCG day (86.4% vs. 84.6%) were similar in both groups.
There was no case of premature luteinization in the two
groups. No statistically significant difference was observed
in implantation (14.8% vs. 13.3%) and the clinical preg-
nancy rate (26.3% vs. 28.0%) when compared the two groups
(Table 2). Six cases were cancelled in study subjects, because
there were no fertilized egg in 5 cases and developmental
arrest of embryo at two cell stage in remaining 1 case. The
cancellation rate was not different (7.6% vs. 3.8%). 
DISCUSSION
Our results indicate that administration of GnRH antag-
onist till the day before hCG administration during flexible
multiple-dose protocol could reduce total dose of GnRH
antagonist without compromising IVF results. Interesting-
ly, omitting GnRH antagonist on hCG day resulted in bet-
ter oocyte maturity and significantly higher fertilization rate
of mature oocytes, although the total number of retrieved
oocytes was comparable between the two study groups. These
findings suggest that omitting GnRH antagonist on ovula-
tion triggering day might have a potential beneficial effect
on the maturity and quality of oocyte. Nonetheless, there
was no significant difference in embryo quality, implanta-
tion and clinical pregnancy rates. Therefore, it is likely that
the discontinuation of GnRH antagonist on the day of hCG
day seems not to affect overall IVF outcomes, at least. To the
best of our knowledge, this is the first comparative study on
the IVF outcomes whether or not the GnRH antagonist
administration was omitted on hCG day.
The GnRH antagonists have emerged as an alternative for
GnRH agonists to prevent premature LH surge during ART.
The GnRH antagonists are advantageous due to an imme-
diate decrease of circulating gonadotropin levels and rapid
reversal when discontinued (1, 2). Discontinuing the admin-
istration of a GnRH antagonist can reverse the suppressive
effect on pulsatile release of LH by pituitary after 456 min
(7.6 hr) (15). The GnRH antagonists immediately act as a
competitive blockade of the GnRH receptors, and do not
induce an initial flare up effect, being frequently observed
in GnRH agonist. However, a slightly lower clinical preg-
nancy rate has been reported with IVF cycles using GnRH
antagonists compared to GnRH agonists; this appears to be
the main reason for a lower utilization of GnRH antagonists
for ovarian stimulation during IVF (17). Ovarian follicles
have development-related requirements for stimulation by
LH, that is, there is a ‘‘threshold’’ for LH requirements dur-
ing folliculogenesis. Beyond this level (high levels), LH sup-
presses aromatase activity and inhibits cell growth. These
findings were observed by different investigators as the ‘‘thresh-
old’’ and ‘‘ceiling’’ levels for LH (framing the so-called LH
window) during the follicular phase of the menstrual and
induced cycles (18, 19). Considering the LH threshold/ceil-
ing effect theory, the serum LH levels on hCG triggering
day could be sustained between the threshold level and the
ceiling level in omitted group. We could not get the patient’s
Duration of COH (days) 9.4±1.8 9.4±1.4 NS 
Dose of gonadotropins (75 IU ampoule) 24.3±6.4 21.9±10.2 NS 
Number of GnRH antagonist injections  3.2±0.9 2.7±0.8 0.036
Serum estradiol on hCG day (pg/mL) 1,095.0±751.8 1,017.2±559.5 NS 
Serum progesterone on hCG day (ng/mL) 1.3±0.6 1.1±0.3 NS
Cycles with premature luteinization (%)* 0 0 -
No. of mature follicles on hCG day
� 6.7±2.9 6.8±3.3 NS 
No. of total oocytes retrieved 7.8±4.5 7.0±4.0 NS
Proportion of mature oocytes (%) 61.7 (316/512) 71.4 (130/182) 0.019
Fertilization rate of mature oocytes (%) 71.8±31.7 86.3±19.7 0.036
Fertilization rate of total oocytes (%) 66.1±27.5 74.9±26.6 NS
No. of cryopreserved embryos 0.25±0.89 0.20±0.82 NS
No. of transferred embryos 2.7±0.7 3.0±0.9 NS
Cumulative embryo score (CES) 45.7±21.6 51.6±29.3 NS
Mean CES
� 17.5±7.6 17.4±8.1 NS
Implantation rate (%) 14.8 (24/162) 13.3 (10/75) NS
Clinical pregnancy rate (%) 26.3 (16/61) 28.0 (7/25) NS
Cancellation rate (%) 7.6 (5/66) 3.8 (1/26) NS
Group A (n=66) Group B (n=26) p value
Table 2. Outcomes of controlled ovarian hyperstimulation and IVF-ET between the two groups
Values are mean±SD.
*, premature luteinization: LH ≥10 mIU/mL and progesterone ≥1.0 ng/mL on hCG day; 
� , mature follicles: follicles ≥15 mm in diameter; 
� , Mean CES=
CES/ No. of embryos transferred.
IVF-ET, in vitro fertilization and embryo transfer; COH, controlled ovarian hyperstimulation.266 H.J. Chang, J.R. Lee, B.C. Jee, et al.
sera at the day after hCG administration, thus we could not
prove this hypothesis directly. This could be a limitation.
Concerns have been raised regarding the possible adverse
effects of GnRH antagonists on the extra-pituitary repro-
ductive organs, which have been claimed to be the cause of
a lower pregnancy rate (20). The expression of GnRH recep-
tor mRNA has been detected in a number of extra-pituitary
tissues (i.e. ovary, testis, placenta, myometrium, and malig-
nant cells of breast, endometrial, ovarian and prostate can-
cers) (21, 22). In ovarian tissue, GnRH may have paracrine
functions during follicular development and indeed induce
transcription of several genes involved in follicular matura-
tion and ovulation (23). In addition, it has been demonstrat-
ed that GnRH and its receptor system could modulate cell
growth in ovarian cancer. Although the regulation mecha-
nisms of gonadal GnRH receptor expression are poorly under-
stood, animal studies have shown that distinct signaling
mechanisms are involved in the pituitary and ovarian GnRH
systems (24). However, the potential adverse effects of GnRH
antagonist on oocyte or endometrium are still controversial.
Several studies comparing the outcome of cryopreserved-
thawed ET for GnRH agonist and GnRH antagonist proto-
cols demonstrated that GnRH antagonist has no direct neg-
ative effect on the quality of oocytes and embryos (25, 26).
With regards the effect of GnRH antagonists versus agonists
on endometrial development, the results are quite conflict-
ing (27, 28).
Although the impact of GnRH antagonists on the oocytes,
embryos and endometrium remained to be elucidated (25-
28), a shorter duration of GnRH antagonists would be help-
ful to the IVF patients. In other words, if the live birth rates
were not affected, any protocols that use the least amount of
GnRH antagonist would be less costly. Under the background
of decreasing exposure to GnRH antagonist, Chen et al. show-
ed that a daily dose of 0.2 mg cetrorelix acetate was effec-
tive to prevent premature LH surge with comparable clini-
cal pregnancies (29). Other researcher revealed that alter-
nate-day administration of ganirelix was as effective as daily
injections in preventing premature luteinization with simi-
lar clinical pregnancy rate (30). Nonetheless, those modified
protocols may have a possible adverse effect on IVF outcome.
There have been several reports demonstrating that the high-
er LH and progesterone levels at the time of triggering are
associated with lower pregnancy rates when the duration of
GnRH antagonist was shortened. One previous study indi-
cated that the stability of LH levels rather than absolute LH
values is associated with clinical pregnancy; no pregnancies
occurred if the LH and progesterone levels were changed too
markedly during GnRH antagonist administration (31). 
In the present study, we discontinued the GnRH antago-
nist on hCG administration day in order to reduce the dura-
tion of antagonist injections. Although premature elevation
of progesterone was not detected in the morning sample of
triggering day, our protocol might lead to premature LH
surge in the evening of triggering day. However, possible
relief of pituitary suppression on triggering day appears not
to affect IVF outcomes. First, the maturation of follicles are
already achieved on hCG day, thus elevation of LH may have
no adverse effect during several hours before hCG adminis-
tration. Second, elevation of LH does not always result in
luteinization of granulose cells or poor IVF outcome. It has
been suggested that a gonadotrophin surge-attenuating fac-
tor (GnSAF) is produced by the overstimulated ovaries in
responsible for the attenuation of the LH surge. In general,
luteinization process needs time, thus LH elevation does not
induce instant progesterone elevation. Moreover, a recent
meta-analysis does not support an association between pro-
gesterone elevation on the day of hCG administration and
the probability of clinical pregnancy in women undergoing
ovarian stimulation with GnRH analogues and gonadotro-
phins for IVF (32).
Interestingly, we found that omitting GnRH antagonist
on hCG day resulted in better oocyte maturity and signifi-
cantly higher fertilization rate of the mature oocytes. Dur-
ing the second half of the follicular phase, as plasma FSH
concentrations decline, the LH-dependent phase of pre-ovu-
latory follicular development proceeds normally only if LH
is present at concentrations over the threshold concentration
and below the ceiling value. When the ceiling exceeds above
the mid-cycle LH surge, further division of the granulosa
cells stops as luteinization proceeds. From the hCG day, relief
of GnRH antagonist suppression may lead to the change of
microenvironment of follicles. Omitting GnRH antagonist
on ovulation triggering day might have a beneficial effect
on the maturity and quality of oocyte. 
The present study demonstrated that omitting GnRH
antagonist on triggering day have comparable IVF outcomes
to standard protocol in women superovulated with recom-
binant FSH using a flexible multiple-dose protocol. Most
importantly and practically, dose of GnRH antagonist was
significantly reduced thus lowering cost and not decreasing
the IVF outcomes. We believe that this new approach is safe
and economic alternative to conventional protocol without
compromising IVF outcomes. 
The main limitation of the present study was in its retro-
spective design. However, we were able to show that the
study groups were comparable with respect to several clini-
cal parameters such as age, body mass index, basal serum
FSH level, duration of infertility, and the causes of infertili-
ty. In addition, the stimulation protocols were identical in
both groups; rFSH with GnRH antagonists flexible multi-
ple-dose protocol. Therefore, the possibility of selection bias
appears to be minimal. 
In conclusion, discontinuation of the GnRH antagonist
on hCG administration day, during a flexible multiple-dose
protocol, could reduce the total dose of the GnRH antago-
nist and thus reduce the cost of the treatment without com-
promising IVF results. Based on the present results, we areCessation of GnRH Antagonist on hCG Day 267
currently conducting a prospective randomized trial to con-
firm our findings.
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